Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 9,303 | 77,648 | 69,716 | 8,249 | 40,560 |
| Cost of Goods | 2,446 | 3,434 | 3,114 | N/A | 2,500 |
| Gross Profit | 6,857 | 74,214 | 66,602 | 8,249 | 38,060 |
| Operating Expenses | 614,673 | 586,850 | 643,348 | 482,731 | 304,800 |
| Operating Income | -607,370 | -512,202 | -576,632 | -474,482 | -266,240 |
| Interest Expense | 81,289 | 80,438 | 46,778 | 36,655 | 8,765 |
| Other Income | 35,408 | 107,988 | 36,956 | 5,649 | -13,580 |
| Pre-tax Income | -653,251 | -484,652 | -586,454 | -505,488 | -288,585 |
| Net Income Continuous | -653,251 | -484,652 | -586,454 | -505,488 | -288,585 |
| Minority Interests | -10,049 | -3,469 | -23,915 | -56,764 | -27,998 |
| Net Income | $-643,202 | $-481,183 | $-562,539 | $-448,724 | $-260,587 |
| EPS Basic Total Ops | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 |
| EPS Basic Continuous Ops | -4.01 | -3.29 | -4.06 | -4.28 | -2.75 |
| EPS Diluted Total Ops | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 |
| EPS Diluted Continuous Ops | -4.01 | -3.29 | -4.06 | -4.28 | -2.75 |
| EPS Diluted Before Non-Recurring Items | -3.95 | -3.79 | -3.90 | -3.80 | -2.48 |
| EBITDA(a) | $-600,876 | $-505,431 | $-570,789 | $-473,026 | $-265,381 |